Support and Resistance Levels
Past performance
About Achyut Healthcare Ltd Achyut Healthcare Limited, originally incorporated as Achyut Securities Private Limited in 1996, transitioned to its current name and public status in 2021. The company specializes in trading a diverse range of pharmaceutical products such as Cenzure, Tacrolimus USP, and Favipiravir. Since entering the pharmaceutical trading sector in 2015, it has built a strong domestic and international presence, serving markets in India, UAE, Kenya, and Nigeria, among others.
Achyut Healthcare's strategic operations are backed by a professional team managing procurement, marketing, and distribution, leveraging multi-location facilities to enhance market penetration. The company raised Rs. 3.6 crore through an IPO in March 2022, reflecting its growth and expansion ambitions. With a focus on high-quality, customized solutions, Achyut Healthcare continues to cater to a wide array of clients including end users, merchants, distributors, and exporters, maintaining a robust pan-India and global market presence.